No insider purchase over the last 90 days. The latest was filed 05 May 2026.
Follow the Avalyn Pharma Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was reported on 5 May 2026 (Acquisition). Among the most active insiders: SR ONE CAPITAL MANAGEMENT, LLC. The full history is accessible without an account.
17
Insider Decl.
n/a
Thresholds
€21M
4 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Avalyn Pharma Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$60.00.
52Σ signal
Buys €21Mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Avalyn Pharma Inc. is a biopharmaceutical company focused on developing treatments for pulmonary diseases. It is listed on NASDAQ under the ticker AVTX.